GOVX (Geovax Labs) Research & Development: $16.67 Mil (TTM As of Mar. 2026)


GOVX Geovax Labs Inc GOVX
22 GF Score
Price $1.34
! 3 Warning Signs
View Full Analysis

What is Geovax Labs Research & Development?

Geovax Labs GOVX +2.29% 22 Research & Development is $16.67 Mil as of Mar. 2026. GuruFocus rates GOVX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Geovax Labs's Research & Development for the three months ended in Mar. 2026 was $3.90 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $16.67 Mil.

Geovax Labs  (NAS:GOVX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Geovax Labs Research & Development Related Terms

Geovax Labs Research & Development Historical Data

* Premium members only.

The historical data trend for Geovax Labs's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs Research & Development Chart

Geovax Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.55 9.12 20.72 23.71 18.12

Geovax Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.36 4.73 5.04 2.99 3.90
GOVX
22GF Score
Geovax Labs Inc GOVX
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geovax Labs Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $16.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $16.67 Mil mean?
Geovax Labs (GOVX) has a Research & Development of $16.67 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Geovax Labs and its competitors.
Is Geovax Labs' Research & Development too high?
Geovax Labs' current Research & Development is $16.67 Mil. Overall, Geovax Labs has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' Research & Development compare to BIVI and KAPA?
Geovax Labs' Research & Development of $16.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Geovax Labs and its competitors. Geovax Labs's current Research & Development is $16.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current Research & Development of $16.67 Mil. The current Research & Development is $16.67 Mil. Geovax Labs' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Geovax Labs (GOVX), the current Research & Development is $16.67 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Geovax Labs Business Description

Address 1955 Lake Park Drive, Suite 300, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score

Get the complete analysis for GOVX

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.34
Price